CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-01 | Jacobs Bruce N. Chief Financial Officer | Grant or award | +13,300 | 40,814 | ||
| 2022-03-01 | Jacobs Bruce N. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2022-03-01 | Gollob Jared Chief Medical Officer | Grant or award | +12,600 | 37,257 | ||
| 2022-03-01 | Gollob Jared Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | −75,800 | 75,800 | ||
| 2022-03-01 | Caughey Elaine Chief Business Officer | Grant or award | +7,000 | 7,000 | ||
| 2022-03-01 | Caughey Elaine Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2022-01-31 | BVF PARTNERS L P/IL Director | Purchase | +20,085 | $40.70 | $817K | 1,900,272 |
| 2022-01-31 | BVF PARTNERS L P/IL Director | Purchase | +14,323 | $40.70 | $583K | 1,395,925 |
| 2022-01-27 | BVF PARTNERS L P/IL Director | Purchase | +58,042 | $38.33 | $2.2M | 1,880,187 |
| 2022-01-27 | BVF PARTNERS L P/IL Director | Purchase | +37,859 | $38.33 | $1.5M | 1,381,602 |
| 2022-01-24 | BVF PARTNERS L P/IL Director | Purchase | +158,041 | $37.76 | $6.0M | 1,822,145 |
| 2022-01-24 | BVF PARTNERS L P/IL Director | Purchase | +114,726 | $37.76 | $4.3M | 1,343,743 |
| 2022-01-18 | MARAGANORE JOHN Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2022-01-14 | Mainolfi Nello Chief Executive Officer | Exercise or conversion | +10,000 | $2.08 | $21K | 482,199 |
| 2022-01-14 | Mainolfi Nello Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −10,000 | 66,424 | ||
| 2022-01-14 | Jacobs Bruce N. Chief Financial Officer | Exercise or conversion | +10,000 | $2.08 | $21K | 27,514 |
| 2022-01-14 | Jacobs Bruce N. Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) | −10,000 | 179,899 | ||
| 2022-01-12 | Jacobs Bruce N. Chief Financial Officer | Exercise or conversion | +15,000 | $2.08 | $31K | 32,514 |
| 2022-01-12 | Jacobs Bruce N. Chief Financial Officer | Sale | −6,427 | $51.21 | $329K | 26,087 |
| 2022-01-12 | Jacobs Bruce N. Chief Financial Officer | Sale | −7,151 | $52.13 | $373K | 18,936 |
Page 39 of 41 · 810 trades